Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
<p>Abstract</p> <p>Background</p> <p>Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-03-01
|
| Series: | Journal of Ovarian Research |
| Online Access: | http://www.ovarianresearch.com/content/3/1/7 |